Phase I and pharmacokinetic study of novel L-nucleoside analog troxacitabine given as a 30-minute infusion every 21 days

Journal of Clinical Oncology

Volumn 20, Issue 10, 2002, Pages 2567-2574

  Belanger, Karl ^a   Moore, Malcolm ^a   Baker, Sharyn D ^a   Dionne, Jeanne ^a   Maclean, Martha ^a   Jolivet, Jacques ^a   Siu, Lillian ^a   Soulières, Denis ^a   Wainman, Nancy ^a   Seymour, Lesley ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; GLUCOSE; NUCLEOSIDE DERIVATIVE; TROXACITABINE;

ADULT; AGED; ALOPECIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRY SKIN; FEMALE; GRANULOCYTOPENIA; HAND FOOT SYNDROME; HEADACHE; HUMAN; INFECTION; LETHARGY; MAJOR CLINICAL STUDY; MALE; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SOLID TUMOR;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTOSINE; DIOXOLANES; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; THROMBOCYTOPENIA; TISSUE DISTRIBUTION;

EID: 0037093236     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.12.047     Document Type: Article

References (13)

1. Anticancer activity of β-L-Dioxolane-cytidine, a novel nucleoside analog with the unnatural L configuration
2. Activity of 2′-deoxy-3′-oxacytidine (BCH-4556) against human tumor colony-forming units
3. Effect of nucleoside analog BCH-4556 on prostate cancer growth and metastases in vitro and in vivo
4. Potent antitumour activity of a novel nucleoside analog, BCH-4556, in human renal cell carcinoma xenograft tumor models
5. A novel cytidine nucleoside analog, BCH-4556, with potent activity against human anthracycline-resistant leukemia
6. L- and d-enantiomers of 2′,3′-dideoxycytidine-5′-triphosphate analogs as substrates for human DNA polymerases
7. Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analog, in human leukemic and solid tumor cell lines
8. Uptake and metabolism of the new anticancer compound β-L-dioxolane-cytidine in human prostate carcinoma DU-145 cells
9. Pharmacodynamics
10. Prediction of creatinine clearance from serum creatinine
11. Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: A phase I and pharmacokinetic study in patients with advanced solid malignancies
12. Troxacitabine (BCH-4556), a novel dioxolane nucleoside analog has activity in patients with advanced leukemia